Heparan sulfate: Biological significance, tools for biochemical analysis and structural characterization

Biomedical Chromatography

Volumn 25, Issue 1, 2011, Pages 11-20

  Malavaki, Christina J ^a   Theocharis, Achilleas D ^a   Lamari, Fotini N ^a   Kanakis, Ioannis ^a,b   Tsegenidis, Theodore ^a   Tzanakakis, George N ^c   Karamanos, Nikos K ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

^c UNIVERSITY OF CRETE   (Greece)

Author keywords

Alzheimer disease; Cancer; Capillary electrophoresis; Heparan sulfate; Heparin; Structure analysis

Indexed keywords

CAPILLARY ELECTROPHORESIS; DIAGNOSIS; FLUOROPHORES; GLUCOSE; POLYSACCHARIDES; SULFUR COMPOUNDS;

ALZHEIMERS DISEASE; BIOCHEMICAL ANALYSIS; BIOLOGICAL SIGNIFICANCE; CANCER; CELLULAR EVENTS; GLYCOSAMINOGLYCANS; HEPARAN SULPHATE; HEPARIN; STRUCTURAL CHARACTERIZATION; STRUCTURE ANALYSIS;

CHAINS;

AMYLOID PRECURSOR PROTEIN; BASIC FIBROBLAST GROWTH FACTOR; CHONDROITIN SULFATE; CYCLIN DEPENDENT KINASE INHIBITOR 1; DERMATAN SULFATE; DISACCHARIDE; GLUCOSAMINE; GLUCURONIC ACID; GLYCOSYLTRANSFERASE; HEPARAN SULFATE; HEPARANASE; HEPARIN; HYALURONIC ACID; IDURONIC ACID; KERATAN SULFATE; LOW MOLECULAR WEIGHT HEPARIN; MONOSACCHARIDE; OLIGOMER; OLIGOSACCHARIDE; PROTEOGLYCAN;

ALZHEIMER DISEASE; ANALYTIC METHOD; ANGIOGENESIS; ANION EXCHANGE CHROMATOGRAPHY; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; BIOLOGICAL MONITORING; BLEEDING; CAPILLARY ELECTROPHORESIS; CAPILLARY ZONE ELECTROPHORESIS; CARBOHYDRATE ANALYSIS; CARBOHYDRATE SYNTHESIS; CHEMICAL ANALYSIS; CHEMICAL MODIFICATION; COMPETITIVE INHIBITION; DERIVATIZATION; DRUG MEGADOSE; EPIMERIZATION; EXTRACELLULAR MATRIX; FLUORESCENCE ANALYSIS; GEL PERMEATION CHROMATOGRAPHY; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LASER; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; REVIEW; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; STOICHIOMETRY; STRUCTURE ANALYSIS; SULFATION;

EID: 78650673333     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1536     Document Type: Review

References (81)

1. Ampofo SA, Wang HM and Linhardt RJ. Disaccharide compositional analysis of heparin and heparin sulfate using capillary zone electrophoresis. Analytical Biochemistry 1991; 199: 249-255.
2. Barash U, Cohen-Kapaln V, Dowek I, Sanderson RD, Ilan N and Vlodavsky I. Proteoglycans in health and disease: New concepts for heparanase function in tumor progression and metastasis. FEBS Journal 2010; 19: 3890-3903.
3. Behr JR., Matsumoto Y, White FM and Sasisekharan R. Quantification of isomers from a mixture of twelve heparin and heparan sulfate disaccharides using tandem mass. Rapid Communications in Mass Spectrometry 2005; 19: 2553-2562.
4. Bergamaschini L, Rossi E, Vergani C and De Simoni MG, Alzheimer's disease: another target for heparin therapy. The Scientific World Journal 2009; 9: 891-908.
5. Bisio A, Vecchietti D, Citterio L, Guerrini M, Raman R, Bertini S, Eisele G, Naggi A, Sasisekharan R and Torri G. Structural features of low-molecular-weight heparins affecting their affinity to antithrombin. Thrombosis and Haemostasis 2009; 102: 865-873.
6. Borsig L. Selectins facilitate carcinoma metastasis and heparin can prevent them. News in Physiological Sciences 2004; 19: 16-21.
7. Carlsson P, Presto J, Spillmann D, Lindahl U and Kjellen L. Heparin/heparan sulfate biosynthesis. The Journal of Biological Chemistry 2008; 283: 20008-20014.
8. Casu B. Structure and active domains of heparin. In Chemistry and Biology of Heparin and Heparan Sulphate, Garg HG, Linhardt RJ, Hales CA (eds). Elsevier: Oxford, 2005; 1-28.
9. Casu B, Vlodavsky I and Sanderson RD. Non-anticoagulant heparins and inhibition of cancer. Pathophysiology of Haemostasis and Thrombosis 2007; 36: 195-203.
10. Castillo GM, Ngo C, Cummings J, Wight TN and Snow AD. Perlecan binds to the beta-amyloid proteins (Aβ) of Alzheimer's disease, accelerates Aβ fibril formation, and maintains Aβ fibril stability. Journal of Neurochemistry 1999; 69: 2452-2465.
11. Chai W, Hounsell EF, Bauer CJ and Lawson AM. Characterisation by LSI-MS and 1H NMR spectroscopy of tetra-, hexa-, and octa-saccharides of porcine intestinal heparin. Carbohydrate Research 1995; 269: 139-156.
12. Chai W, Luo J, Lim CK and Lawson AM. Characterization of heparin oligosaccharide mixtures as ammonium salts using electrospray mass spectrometry. Analytical Chemistry 1998; 70: 2060-2066.
13. Chatzinikolaou G, Nikitovic D, Berdiaki A, Zafiropoulos A, Katonis P, Karamanos NK and Tzanakakis GN. Heparin regulates colon cancer cell growth through p38 mitogen-activated protein kinase signalling. Cell Proliferation 2010; 43: 9-18.
14. Das P, Ziada K, Steinhubl S, Moliterno DJ, Hamdalla H, Jozic J, Mukherjee D and Lexington KY. Heparin-induced thrombocytopenia and cardiovascular diseases. American Heart Journal 2006; 152: 19-26.
15. Desaire H and Leary JA. Detection and quantification of the sulfated disaccharides in chondroitin sulfate by electrospray tandem mass spectrometry. Journal of the American Society for Mass Spectrometry 2000, 11: 916-920.
16. Dimitrellos V, Lamari FN, Militsopoulou M, Kanakis I and Karamanos NK. Capillary electrophoresis and enzyme solid phase assay for examining the purity of a synthetic heparin proteoglycan-like conjugate and identifying binding to basic fibroblast growth factor. Biomedical Chromatography 2003; 17: 42-47.
17. El Rassi Z, Postlewait J, Mechref Y and Ostrander GK. Capillary electrophoresis of carboxylated carbohydrates. III. Selective precolumn derivatization of glycosaminoglycan disaccharides with 7-aminonaphthalene-1, 3-disulfonic acid fluorescing tag for ultrasensitive laser-induced fluorescence detection. Analytical Biochemistry 1997; 244: 283-290.
18. Esko J and Lindahl U. Molecular diversity of heparan sulfate. Journal of Clinical Investigation 2001; 108: 169-173.
19. Fux L, Ilan N, Sanderson RD and Vlodavsky I. Heparanase: busy at the cell surface. Trends in Biochemical Sciences 2009; 34: 511-519.
20. Gallagher JT. Structure-activity relationship of heparin sulfate. Biochemical Society Transactions 1997; 25: 1206-1209.
21. Grobe K, Ledin J, Ringvall M, Holmborn K, Forsberg E, Esko JD and Kjellén L. Heparan sulfate and development: differential roles of the N-acetylglucosamine N-deacetylase/N-sulfotransferase isozymes. Biochimica et Biophysica Acta 2002; 1573: 209-215.
22. Guerrini M, Beccati D, Shriver Z, Naggi A, Viswanathan K, Bisio A, Capila I, Lansing JC, Guglieri S, Fraser B, Al-Hakim A, Gunay NS, Zhang Z, Robinson L, Buhse L, Nasr M, Woodcock J, Langer R, Venkataraman G, Linhardt RJ, Casu B, Torri G and Sasisekharan R. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nature Biotechnology 2008; 26: 669-675.
23. Guerrini M, Shiver Z, Bisio A, Naggi A, Casu B, Sasisekharan R and Torri G. The tainted heparin story: an update. Thrombosis and Haemostasis 2009, 102: 907-911.
24. Hampson IN and Gallagher JT. Separation of radiolabelled glycosaminoglycan oligosaccharides by polyacrylamide-gel electrophoresis. Biochemical Journal 1984; 221: 697-705.
25. Hourigan LA, Walters DL, Keck SA and Dec GW. Heparin induced thrombocytopenia: a common complication in cardiac transplant recipients. Journal of Heart Lung Transplantation 2002; 21: 1283-1289.
26. Ilan N, Elkin M and Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. International Journal of Biochemistry and Cell Biology 2006; 38: 2018-2039.
27. Iozzo RV and Karamanos NK. Proteoglycans in health and disease: emerging concepts and future directions. FEBS Journal 2010; 19: 3863.
28. Iozzo RV and Schaefer L. Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS Journal 2010; 19: 3864-3875.
29. Karamanos NK. Proteoglycans: biological roles and strategies for isolation and determination of their glycan constituents. In Proteome and Protein Analysis, Kamp M, Kyriakides D, Choli-Papadopoulou T (eds). Springer: Heidelberg, 1999; 341-363.
30. Karamanos NK, Syrokou A, Vanky P, Nurminen M and Hjerpe A. Determination of 24 variously sulfated galactosaminoglycan- and hyaluronan-derived disaccharides by high-performance liquid chromatography. Analytical Biochemistry 1994; 221: 189-199.
31. Karamanos NK, Vanky P, Tzanakakis GN and Hjerpe A. High performance capillary electrophoresis method to characterize heparin and heparan sulfate disaccharides. Electrophoresis 1996; 17(2): 391-395.
32. Karamanos NK, Vanky P, Tzanakakis GN, Tsegenidis T and Hjerpe A. Ion-pair high-performance liquid chromatography for determining disaccharide composition in heparin and heparin sulphate. Journal of Chromatography A 1997; 765: 169-179.
33. Kariya Y, Hermann J, Suzuki K, Isomura T and Ishihara M. Disaccharide analysis of heparin and heparan sulfate using deaminative cleavage with nitrous acid and subsequent labeling with paranitrophenyl hydrazine. Journal of Biochemistry 1998; 123: 240-246.
34. Khoo KH, Morris HR, McDowell RA, Dell A, Maccarana M and Lindahl U. FABMS/derivatisation strategies for the analysis of heparin-derived oligosaccharides. Carbohydrate Research 1993; 244: 205-223.
35. Kim BT, Kitagawa H, Tamura J, Saito T, Kusche-Gullberg M, Lindahl U and Sugahara K. Human tumor suppressor EXT gene family members EXTL1 and EXTL3 encode α1, 4-N-acetylglucosaminyltransferases that likely are involved in heparan sulfate/heparin biosynthesis. Proceedings of the National Academy of Science USA 2001; 98: 7176-7181.
36. Kinoshita A and Sugahara K. Microanalysis of glycosaminoglycan-derived oligosaccharides labeled with a fluorophore 2-aminobenzamide by high-performance liquid chromatography: application to disaccharide composition analysis and exosequencing of oligosaccharides. Analytical Biochemistry 1999; 269: 367-378.
37. Kitagawa H, Kinoshita A and Sugahara K. Microanalysis of glycosaminoglycan-derived disaccharides labeled with a fluorophore 2-aminoacridone by capillary electrophoresis and high-performance liquid chromatography. Analytical Biochemistry 1995; 232: 114-121.
38. Kitagawa H, Shimakawa H and Sugahara K. The tumor suppressor EXT-like gene EXTL2 encodes an alpha1, 4-N-acetylhexosaminyltransferase that transfers N-acetylglucosamine to the common glycosaminoglycan-protein linkage region. The Journal of Biological Chemistry 1999; 274: 13933-13937.
39. Kolset S and Tveit H. Serglycin-structure and biology. Cellular and Molecular Life Sciences 2008; 65: 1073-1085.
40. Kuberan B, Lech M, Zhang L, Wu Z.L, Beeler DL and Rosenberg RD. Analysis of heparan sulfate oligosaccharides with ion pair-reverse phase capillary high performance liquid chromatography-microelectrospray ionization time-of-flight mass spectrometry. Journal of the American Chemical Society 2002, 124: 8707-8718.
41. Lamari FN, Militsopoulou M, Gioldassi X and Karamanos NK. Capillary electrophoresis: a superior miniaturized tool for analysis of the mono-, di-, and oligosaccharide constituents of glycan moieties in proteoglycans. Fresenius' Journal of Analytical Chemistry 2001; 371: 157-167.
42. Lamari FN, Militsopoulou M, Mitropoulou TN, Hjerpe A and Karamanos NK. Analysis of glycosaminoglycan-derived disaccharides in biologic samples by capillary electrophoresis and protocol for sequencing glycosaminoglycans. Biomedical Chromatography 2002; 16: 95-102.
43. Lever R and Page CP. Novel drug development opportunities for heparin. Nature Reviews Drug Discovery 2002; 1: 140-148.
44. Li JP and Vlodavsky I. Heparin, heparan sulfate and heparanase in inflammatory reactions. Thrombosis and Haemostasis 2009; 102: 823-828.
45. Lindahl B, Westling C, Gimenez-Gallego G, Lindahl U and Salmivirta M. Common binding sites for β-amyloid fibrils and fibroblast growth factor-2 in HS from human cerebral cortex. The Journal of Biological Chemistry 1999; 274: 30631-30635.
46. Lindahl U. What else can 'heparin' do? Haemostasis 1999; 29(suppl. S1): 38-47.
47. Lindhardt RJ, Turnbull JE, Wang HM, Loganathan D and Gallagher JT. Examination of the substrate specificity of heparin and heparan sulfate lyases. Biochemistry 1990; 29: 2611-2617.
48. Mallis LM, Wang HM, Loganathan D and Linhardt RJ. Sequence analysis of highly sulfated heparin-derived oligosaccharides using fast atom bombardment mass spectrometry. Analytical Chemistry 1989; 61: 1453-1458.
49. Manon-Jensen T, Itoh Y and Couchman JR. Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS Journal 2010; 19: 3876-3889.
50. McLaurin J, Franklin T, Kuhns W and Fraser P. A sulfated proteoglycan aggregation factor mediates amyloid-β peptide fibril formation and neurotoxicity. Amyloid 1999; 6: 233-243.
51. Merry CLR, Lyon M, Deakin JA, Hopwood JJ and Gallagher JT. Highly sensitive sequencing of the sulfated domains of heparan sulfate. The Journal of Biological Chemistry 1999; 274: 18455-18462.
52. Militsopoulou M, Lamari F, Hjerpe A and Karamanos NK. Determination of twelve heparin- and heparan sulfate-derived disaccharides as 2-aminoacridone derivatives by capillary zone electrophoresis using ultraviolet and laser-induced fluorescence detection. Electrophoresis 2002; 23: 1104-1109.
53. Militsopoulou M, Lamari F and Karamanos NK. Capillary electrophoresis: a tool for studying interactions of glycans/proteoglycans with growth factors. Journal of Pharmaceutical and Biomedical Analysis 2003; 32: 823-828.
54. Pervin A, Gallo C, Jandik K, Han X and Linhardt R. Preparation and structural characterization of large heparin-derived oligosaccharides. Glycobiology 1995; 5: 83-95.
55. Plaas AH, Hascall VC and Midura RJ. Ion exchange HPLC microanalysis of chondroitin sulfate: quantitative derivatization of chondroitin lyase digestion products with 2-aminopyridine. Glycobiology 1996; 6: 823-829.
56. Powell AK, Yates E A, Fernig DG and Turnbull JE. Interactions of heparin/heparan sulfate with proteins: appraisal of structural factors and experimental approaches. Glycobiology 2004; 12: 17R-30R.
57. Potapenko IO, Haakensen VD, Lüders T, Helland A, Bukholm I, Sørlie T, Kristensen VN, Lingjaerde OC and Børresen-Dale AL. Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. Molecular Oncology 2010; 4: 98-118.
58. Purushothaman A, Uyama T, Kobayashi F, Yamada S, Sugahara K, Rapraeger AC and Sanderson RD. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 2010; 115: 2449-2457.
59. Pye DA, Vives RR, Turnbull JE, Hyde P and Gallagher JT. Heparan sulfate oligosaccharides require 6-O-sulfation for promotion of basic fibroblast growth factor mitogenic activity. The Journal of Biological Chemistry 1998; 273: 22936-22942.
60. Rhomberg AJ, Ernst S, Sasisekharan R and Biemann K. Mass spectrometric and capillary electrophoretic investigation of the enzymatic degradation of heparin-like glycosaminoglycans. Proceedings of the National Academy of Science USA 1998; 95: 4176-4181.
61. Rice KG, Rottink MK and Linhardt RJ. Fractionation of heparin-derived oligosaccharides by gradient polyacrylamide-gel electrophoresis. Biochemical Journal 1987; 244: 515-522.
62. Ruiz-Calero V, Moyano E, Puignou L and Galceran MT. Pressure-assisted capillary electrophoresis-electrospray ion trap mass spectrometry for the analysis of heparin depolymerised disaccharides. Journal of Chromatography A 2001; 914: 277-291.
63. Scholefield Z, Yates EA, Wayne G, Amour A, McDowell W and Turnbull JE. Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's beta-secretase. Journal of Cell Biology 2003; 163: 97-107.
64. Skidmore M, Atrih A, Yates E and Turnbull JE. Labelling heparan sulphate saccharides with chromophore, fluorescence and mass tags for HPLC and MS separations. Methods in Molecular Biology (Clifton, NJ) 2009; 534: 157-169.
65. Sorensen HT, Mellemkjaer L, Olsen JH and Baron JA. Prognosis of cancers associated with venous thromboembolism. New England Journal of Medicine 2000; 343: 1846-1850.
66. Stringer SE, Kandola BS, Pye DA and Gallagher JT. Heparin sequencing. Glycobiology 2003; 13: 97-107.
67. Thanawiroon C, Rice KG, Toida T, Linhardt RJ. Liquid chromatography/mass spectrometry sequencing approach for highly sulphated heparin-derived oligosaccharides. The Journal of Biological Chemistry 2004, 279: 2608-2615.
68. Theocharis AD, Skandalis SS, Tzanakakis GN and Karamanos NK. Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS Journal 2010; 19: 3904-3923.
69. Toyoda H, Nagashima T, Hirata R, Toida T and Imanari T. Sensitive high-performance liquid chromatographic method with fluorometric detection for the determination of heparin and heparan sulfate in biological samples: application to human urinary heparan sulfate. Journal of Chromatography B 1997; 704: 19-24.
70. Turnbull JE, Hopwood JJ and Gallagher JT. A strategy for rapid sequencing of heparan sulfate and heparin saccharides. Proceedings of the National Academy of Science USA 1999; 96: 2698-2703.
71. Venkataraman G, Shiver Z, Raman R and Sasisekharan R. Sequencing complex polysaccharides. Science 1999; 286: 537-542.
72. Verbeek MM, Otte-Holler I, Veerhuis R, Ruiter DJ and De Waal RM. Distribution of Aβ-associated proteins in cerebrovascular amyloid of Alzheimer's disease. Acta Neuropathologica 1998; 96: 628-636.
73. Vivès RR, Pye DA, Salmivirta M, Hopwood JJ, Lindahl U, Gallagher JT. Sequence analysis of heparan sulphate and heparin oligosaccharides. Biochemical Journal 1999; 339: 767-773.
74. Vlodavsky I, Ishai-Michaeli R, Mohsen M, Bar-Shavit R, Catane R, Ekre HT and Svahn CM. Modulation of neovascularization and metastasis by species of heparin. In Heparin and Related Polysaccharides, Lane DA, Björk I, Lindahl U (eds). Plenum Press: New York, 2006; 317-327.
75. Vlodavsky I, Ilan N, Nadir Y, Brenner B, Katz B-Z, Naggi A, Torri G, Casu B and Sasisekharan R. Heparanase, heparin and the coagulation system in cancer progression. Thrombosis Research 2007; 120: 112-120.
76. Vynios DH, Karamanos NK and Tsiganos CP. Advances in analysis of glycosaminoglycans: its application for the assessment of physiological and pathological states of connective tissues. Journal of Chromatography B 2002; 781: 21-38.
77. Walker A, Turnbull JE and Gallagher JT. Specific heparan sulfate saccharides mediate the activity of basic fibroblast growth factor. The Journal of Biological Chemistry 1994; 269: 931-935.
78. Warkentin TE and Greinacher A. Heparin induced thrombocytopenia and cardiac surgery. Annals of Thoracic Surgery 2003; 76: 638-648.
79. Yamada S, Yoshida K, Sugiura M, Sugahara K, Khoo K, Morris H and Dell A. Structural studies on the bacteria lyase-resistant tetrasaccharides derived from the antithrombin binding site of porcine mucosal intestinal heparin. The Journal of Biological Chemistry 1993; 268: 4780-4787.
80. Yamada S, Yamane Y, Tsuda H, Yoshida K and Sugahara K. A major common trisulfated hexasaccharide core sequence, hexuronic acid(2-sulfate)-glucosamine(N-sulfate)-iduronic acid-N-acetylglucosamine-glucuronic acid-glucosamine(N-sulfate), isolated from the low sulfated irregular region of porcine intestinal heparin. The Journal of Biological Chemistry 1998; 273: 1863-1871.
81. Zetser A, Bashenko Y, Edovitsky E, Levy- Adam F, Vlodavsky I and Ilan N. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Research 2006; 66: 1455-1463.